A phase 1/2 trial of Super DC Vaccine in advanced solid tumours, run by Shanghai Cell Therapy Group Co.,Ltd, now recruiting.
Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors is a phase 1/2 interventional study registered as NCT07146672 by Shanghai Cell Therapy Group Co.,Ltd, with 12 participants planned, started 2025-07-31 and due to reach its primary completion in 2026-12-31. Interventions recorded: Super DC Vaccine.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.